Management strategies for patients with amyotrophic lateral sclerosis from diagnosis through death

Neurologist

Volumn 11, Issue 5, 2005, Pages 257-270

  Simmons, Zachary ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Amyotrophic lateral sclerosis; End of life care; Hospice; Palliative care; Quality of life

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTIOXIDANT; ATROPINE; BACLOFEN; BENZATROPINE MESILATE; BOTULINUM TOXIN; CITALOPRAM; DANTROLENE; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; GLUTAMATE RECEPTOR ANTAGONIST; GLYCOPYRRONIUM BROMIDE; HYOSCYAMINE; LEVODOPA; LITHIUM; MINOCYCLINE; NIMODIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; RILUZOLE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIZANIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIHEXYPHENIDYL;

AMYOTROPHIC LATERAL SCLEROSIS; BREATHING; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEPRESSION; DISEASE COURSE; EXERCISE; HUMAN; LIFESPAN; MUSCLE CRAMP; NEUROMUSCULAR DISEASE; NUTRITION; PAIN; PRIORITY JOURNAL; PSEUDOBULBAR PALSY; QUALITY OF LIFE; REVIEW; SECRETION; SOMNOLENCE; SPASTICITY; SUICIDE; URINE RETENTION;

AMYOTROPHIC LATERAL SCLEROSIS; HOSPICES; HUMANS; NEUROPROTECTIVE AGENTS; NUTRITION PHYSIOLOGY; PAIN; QUALITY OF LIFE; RILUZOLE; SPIRITUALITY; SUICIDE;

EID: 24944590352     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000178758.30374.34     Document Type: Review

References (197)

1. Mitsumoto H, Chad DA, Pioro EP. Amyotrophic Lateral Sclerosis. Philadelphia: FA Davis; 1998.
2. WHOQOL: Measuring Quality of Life. Geneva: World Health Organization; 1997.
3. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA. 1994;272:619-626.
4. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med. 1996;334:835-840.
5. Simmons Z, Bremer BA, Robbins RA, et al. Quality of life in ALS depends on factors other than strength an physical function. Neurology. 2000;55:388-392.
6. Neudert C, Wasner M, Borasio GD. Patients' assessment of quality of life instruments: a randomized study of SIP, SF-36 and SEIQoL-DW in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2001;191:103-109.
7. Robbins RA, Simmons Z, Bremer BA, et al. Quality of life in ALS is maintained as physical function declines. Neurology. 2001;56:442-444.
8. Bromberg MB, Forshew DA. Comparison of instruments addressing quality of life in patients with ALS and their caregivers. Neurology. 2002;58:320-322.
9. Goldstein LH, Atkins L, Leigh PN. Correlates of quality of life in people with motor neuron disease (MND). Amytroph Lateral Scler Other Motor Neuron Disord. 2002;3:123-129.
10. Lou J-S, Reeves A, Benice T, et al. Fatigue and depression are associated with poor quality of life in ALS. Neurology. 2003;60:122-123.
11. Moss AH, Casey P, Stocking CB, et al. Home ventilation for amyotrophic lateral sclerosis: outcomes, costs, and patient, family, and physician attitudes. Neurology. 1993;43:438-443.
12. Carlson D. Speaking from experience: ALS patients can lead happy lives. RN. 1995;58:10.
13. Abramson N. Quality of life: who can make the judgment? Am J Med. 1996;100:365-366.
14. McDonald ER, Hillel A, Wiedenfeld SA. Evaluation of the psychological status of ventilatory-supported patients with ALS/MND. Palliat Med. 1996;10:35-41.
15. Moss AH, Oppenheimer EA, Casey P, et al. Patients with amyotrophic lateral sclerosis receiving long-term mechanical ventilation: advance care planning and outcomes. Chest. 1996;110:249-255.
16. Gelinas DF, O'Connor P, Miller RG. Quality of life for ventilator-dependent ALS patients and their caregivers. J Neurol Sci. 1998;160(suppl 1):S134-S136.
17. Kaub-Wittemer D, von Steinbuchel N, Wasner M, et al. Quality of life and psychosocial issues in ventilated patients with amyotrophic lateral sclerosis and their caregivers. J Pain Symptom Manage. 2003;26:890-896.
18. Slevin ML, Plant H, Lynch D, et al. Who should measure the quality of life, the doctor or the patient? Br J Cancer. 1988;57:109-112.
19. Bach JR, Barnett V. Ethical considerations in the management of individuals with severe neuromuscular disorders. Am J Phys Med Rehabil. 1994;73:134-140.
20. Gerhart KA, Koziol-McLain J, Lowenstein SR, et al. Quality of life following spinal cord injury: knowledge and attitudes of emergency care providers. Ann Emerg Med. 1994;23:807-812.
21. Rothwell PM, McDowell Z, Wong CK, et al. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ. 1997;314:1580-1583.
22. Trail M, Nelson ND, Van JN, et al. A study comparing patients with amyotrophic lateral sclerosis and their caregivers on measures of quality of life, depression, and their attitudes toward treatment options. J Neurol Sci. 2003;209:79-85.
23. Adelman EE, Albert SM, Rabkin JG, et al. Disparities in perceptions of distress and burden in ALS patients and family caregivers. Neurology. 2004;62:1766-1770.
24. Bergner M, Bobbitt RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care. 1981;19:787-805.
25. McGuire D, Garrison L, Armon C, et al. Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. Neurology. 1996;46:1442-1444.
26. McGuire D, Garrison L, Armon C, et al. A brief quality-of-life measure for ALS clinical trials based on a subset of items from the sickness impact profile. J Neurol Sci. 1997;152(suppl):S18-S22.
27. Cohen SR, Mount BM, Strobel MG, et al. The McGill quality of life questionnaire: a measure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability. Palliat Med. 1995;9:207-219.
28. Cohen SR, Hassan SA, Lapointe BJ, et al. Quality of life in HIV disease as measured by the McGill Quality of Life Questionnaire. AIDS. 1996;10:1421-1427.
29. Cohen SR, Mount BM, Tomas JJN, et al. Existential well-being is an important determinant of quality of life. Cancer. 1996;77:576-586.
30. Cohen SR, Mount BM, Bruera E, et al. Validity of the McGill Quality of Life Questionnaire in the palliative care setting: a multi-centre Canadian study demonstrating the importance of the existential domain. Palliat Med. 1997;11:3-20.
31. Hickey AM, Bury G, O'Boyle CA, et al. A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV/AIDS. BMJ. 1996;313:29-33.
32. Hickey A, O'Boyle CA, McGee HM, et al. The schedule for the evaluation of individual quality of life. In: Joyce CRB, O'Boyle CA, McGee HM, eds. Individual Quality of Life: Approaches to Conceptualisation and Assessment. The Netherlands: Harwood Academic Publishers; 1999:119-133.
33. Waldron D, O'Boyle CA, Kearney M, et al. Quality-of-life measurement in advanced cancer: assessing the individual. J Clin Oncol. 1999;17:3603-3611.
34. Jenkinson C, Fitzpatrick R, Brennan C, et al. Evidence for the validity and reliability of the ALS assessment questionnaire: The ALSAQ-40. Amyotroph Lateral Scler Other Motor Neuron Disord. 1999;1:33-40.
35. Reed PG. Religiousness among terminally ill and healthy adults. Res Nurs Health. 1986;9:35-41.
36. Idler EL. Religious involvement and the health of the elderly: some hypothesis and an initial test. Social Forces. 1987;66:226-238.
37. Reed PG. Spirituality and well-being in terminally ill hospitalized adults. Res Nurs Health. 1987;10:335-344.
38. Simmons Z, Felgoise SH, Bremer BA, et al. Development and validation of an ALS-specific quality of life instrument. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(suppl 2):140.
39. Buckman R. Talking to patients about cancer. BMJ. 1996 313:699-700.
40. Benson J, Britten N. How much truth and to whom? Respecting the autonomy of cancer patients when talking with their families-ethical theory and the patients' view. BMJ. 1996;313:729-731.
41. Meredith C, Symonds P, Webster L, et al. Information needs of cancer patients in the west of Scotland. BMJ. 1996;313:724-726.
42. Borasio GD, Sloan R, Pongratz DE. Breaking the news in amyotrophic lateral sclerosis. J Neurol Sci. 1998;160(suppl 1):S127-S133.
43. Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review). Neurology. 1999;52:1311-1323.
44. McCluskey L, Casarett D, Siderowf A. Breaking the news: a survey of ALS patients and their caregivers. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:131-135.
45. Bensimon G, Lacomblez L, Meininger V, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330:585-591.
46. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347:1425-1431.
47. Traynor BJ, Alexander M, Corr B, et al. An outcome study of riluzole in amyotrophic lateral sclerosis: a population-based study in Ireland, 1996-2000. J Neurol. 2003;250:473-479.
48. Bensimon G, Lacomblez L, Delumeau JC, et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002;249:609-615.
49. Cassiman D, Thomeer M, Verbeken E, et al. Hypersensitivity pneumonitis possibly caused by riluzole therapy in ALS. Neurology. 2003;61:1150-1151.
50. Weber G, Bitterman H. Biluzole-induced neutropenia. Neurology. 2004;62:1648.
51. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2002;10:268-278.
52. Van Den Bosch L, Tilkin P, Lemmens G, et al. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport. 2002;13:1067-1070.
53. Zhu S, Stravrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002;417:74-78.
54. Gordon PH, Moore DH, Gelinas DF, et al. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology. 2004;62:1845-1847.
55. Fahn S. Parkinson's disease. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(suppl 1):26-30.
56. Kriz J, Gowing G, Julien J-P. Efficient three-drug cocktail for disease induced by mutant Superoxide dismutase. Ann Neurol. 2003;53:429-436.
57. O'Brien T, Kelly M, Saunders C. Motor neuron disease: a hospice perspective. BMJ. 1992;304:471-473.
58. Mandler RN, Anderson FA, Miller RG, et al. The ALS patient care database: insights into end-of-life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:203-208.
59. Neudert C, Oliver D, Wasner M, et al. The course of the terminal phase in patients with amyotrophic lateral sclerosis. J Neurol. 2001;248:612-616.
60. Stambler N, Charatan M, Cedarbaum JM, et al. Prognostic indicators of survival in ALS. Neurology. 1998;50:66-72.
61. Kleopa KA, Sherman M, Neal B, et al. BIPAP improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci. 1999;164:82-88.
62. Aboussouan LA, Khan SU, Banerjee M, et al. Objective measures of the efficacy of noninvasive positive-pressure ventilation in amyotrophic lateral sclerosis. Muscle Nerve. 2001;24:403-409.
63. Pinto AC, Evangelista T, Carvalho M, et al. Respiratory assistance with a non-invasive ventilator (BiPAP) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci. 1995;129(suppl):19-26.
64. Aboussouan LS, Khan SU, Meeker DP, et al. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med. 1997;127:450-453.
65. Bach JR. Amyotrophic lateral sclerosis: prolongation of life by noninvasive respiratory aids. Chest. 2002;122:92-98.
66. Bourke SC, Bullock RE, Williams TL, et al. Noninvasive ventilation in ALS: indications and effect on quality of life. Neurology. 2003;61:171-177.
67. Butz M, Wollinsky KH, Wiedemuth-Catrinescu U, et al. Longitudinal effects of noninvasive positive-pressure ventilation in patients with amyotrophic lateral sclerosis. Am J Phys Med Rehabil. 2003;82:597-604.
68. Newsom-Davis IC, Lyall RA, Leigh PN, et al. The effect of non-invasive positive pressure ventilation (NIPPV) on cognitive function in amyotrophic lateral sclerosis (ALS): a prospective study. J Neurol Neurosurg Psychiatry. 2001;71:482-487.
69. Jackson CE, Rosenfeld J, Moore DH, et al. A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci. 2001;191:75-78.
70. Lyall RA, Donaldson N, Fleming T, et al. A prospective study of quality of life in ALS patients treated with noninvasive ventilation. Neurology. 2001;57:153-156.
71. Morgan RK, McNally S, Alexander M, et al. Use of sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med. 2005;171:269-274.
72. Varrato J, Siderowf A, Damiano P, et al. Postural change of forced vital capacity predicts some respiratory symptoms in ALS. Neurology. 2001;57:357-359.
73. Lyall RA, Donaldson N, Polkey MI, et al. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain. 2001;124:2000-2013.
74. Elman LB, Siderowf AD, McCluskey LF. Nocturnal oximetry: utility in the respiratory management of amyotrophic lateral sclerosis. Am J Phys Med Rehabil. 2003;82:866-870,
75. Consensus conference. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation-a consensus conference report. Chest. 1999;116:521-534.
76. Pinto A, de Carvalho M, Evangelista T, et al. Nocturnal pulse oximetry: a new approach to establish the appropriate time for non-invasive ventilation in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:31-35.
77. Sivak ED, Shefner JM, Mitsumoto H, et al. The use of non-invasive positive pressure ventilation (NIPPV) in ALS patients: a need for improved determination of intervention timing. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:139-145.
78. Bradley WG, Anderson F, Bromberg M, et al. Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter. Neurology. 2001;57:500-504.
79. Hayashi H, Oppenheimer EA. ALS patients on TPPV: totally locked-in state, neurologic findings and ethical implications. Neurology. 2003;61:135-137.
80. Chio A, Mora G, Leone M, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology. 2002;59:99-103.
81. Desport JC, Preux PM, Truong TC, et al. Nutritional status is a prognostic factor for survival in ALS patient. Neurology. 1999;53:1059-1063.
82. Preshaw RM. A percutaneous method for inserting a feeding tube. Surg Gynecol Obstet. 1981;152:658-660.
83. Mazzini L, Corra T, Zaccala M, et al. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol. 1995;242:695-698.
84. Mathus-Vliegen LMH, Louwerse LS, Merkus MP, et al. Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function. Gastrointest Endosc. 1994;40:463-469.
85. Chio A, Finocchiaro E, Meineri P, et al. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. Neurology. 1999;53:1123.
86. Desport JC, Preux PM, Truong CT, et al. Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:91-96.
87. Mitsumoto H, Davidson M, Moore D, et al. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:177-185.
88. Boitano LJ, Jordan T, Benditt JO. Noninvasive ventilation allows gastrostomy tube placement in patients with advanced ALS. Neurology. 2001;56:413-414.
89. Gregory S, Siderowf A, Golaszewski AL, et al. Gastrostomy insertion in ALS patients with low vital capacity: respiratory support and survival. Neurology. 2002;58:485-487.
90. Thornton FJ, Fotheringham T, Alexander M, et al. Amyotrophic lateral sclerosis: enterai nutrition provision-endoscopic or radiologic gastrostomy? Radiology. 2002;224:713-717.
91. Chio A, Galletti R, Finocchiaro C, et al. Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS. J Neurol Neurosurg Psychiatry. 2004;75:645-647.
92. Shaw AS, Ampong MA, Rio A, et al. Entristar skin-level gastrostomy tube: primary placement with radiologic guidance in patients with amyotrophic lateral sclerosis. Radiology. 2004;233:392-399.
93. Newall AR, Orser R, Hunt M. The control of oral secretions in bulbar ALS/MND. J Neurol Sci. 1996;139(suppl):43-44.
94. Goode RL, Smith RA. The surgical management of sialorrhea. Laryngoscope. 1970;80:1078-1089.
95. Charchaflie RJ, Fernandez LB, Perec CJ, et al. Functional studies of the parotid and pancreas glands in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 1974;37:863-867.
96. Giess R, Naumann M, Werner E, et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2000;69:121-123.
97. Verma A, Steele J, Singer C. Botulinum toxin improves sialorrhea and quality of life in bulbar amyotrophic lateral sclerosis. Neurology. 2002;58(suppl 3):A199.
98. Scott KR, Kothari MJ, Simmons Z, et al. Parotid gland injections of botulinum A toxin for refractory sialorrhea in patients wit amyotrophic lateral sclerosis-a pilot study. Neurology. 2004;62(suppl 5):A136.
99. Lipp A, Trottehberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003;61:1279-1281.
100. Borg M, Hirst F. The role of radiation therapy in the management of sialorrhea. Int J Radiat Oncol Biol Phys. 1998;41:1113-1119.
101. Harriman M, Morrison M, Hay J, et al. Use of radiotherapy for control of sialorrhea in patients with amyotrophic lateral sclerosis. J Otolaryngol. 2001;30:242-245.
102. Stalpers LJA, Moser EC. Results of radiotherapy for drooling in amyotrophic lateral sclerosis. Neurology. 2002;58:1308.
103. Mustfa N, Aiello M, Lyall RA, et al. Cough augmentation in amyotrophic lateral sclerosis. Neurology. 2003;61:1285-1287.
104. Murphy J. Communication strategies of people with ALS and their partners. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:121-126.
105. Mukund J, Kaplan M, Senno RG, et al. Pathological crying and laughing: treatment with sertraline. Arch Phys Med Rehabil. 1996;77:1309-1311.
106. Lawson IR, MacLeod RDM. The use of imipramine ('Tofranil') and other drugs in organic emotionalism. Br J Psychiatry. 1969;115:281-285.
107. Schiffer RB, Cash J, Herndon RM. Treatment of emotional lability with low-dosage tricyclic antidepressants. Psychosomatics. 1983;24:1094-1096.
108. Seliger GM, Nornstein A. Serotonin, fluoxetine, and pseudobulbar affect. Neurology. 1989;39:1400.
109. Lauterbach EC, Schweri MM. Amelioration of pseudobulbar affect by fluoxetine: possible alteration of dopamine-related pathophysiology by a selective serotonin reuptake inhibitor. J Clin Psychopharmacol. 1991;11:392-393.
110. Iannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin Neuropharmacol. 1996;19:532-535.
111. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med. 1985;312:1480-1482.
112. Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. Lancet. 1993;342:837-839.
113. Caroscio JT, Cohen JA, Gudesblatt M. Amitriptyline in amyotrophic lateral sclerosis. N Engl J Med. 1985;313:1478.
114. Udaka T, Yamao S, Nagata H, et al. Pathological laughing and crying treated with levodopa. Arch Neurol. 1984;41:1095-1096.
115. Shader RI. Does lithium both cause and treat pseudobulbar affect? J Clin Psychopharmacol. 1992;12:360.
116. Casey P. Occupational therapy. In: Mitsumoto H, Munsat TL, eds. Amyotrophic Lateral Sclerosis: A Guide for Patients and Families, 2nd ed. New York: Demos; 2001:103-111.
117. Dal Bello-Haas V. Physical therapy. In: Mitsumoto H, Munsat TL, eds. Amyotrophic Lateral Sclerosis: A Guide for Patients and Families, 2nd ed. New York: Demos; 2001:93-102.
118. Krivickas LS. Rehabilitation issues. In: Mitsumoto H, Munsat TL, eds. Amyotrophic Lateral Sclerosis: A Guide for Patients and Families, 2nd ed. New York: Demos; 2001:79-91.
119. Richer CB. Wheelchair selection. In: Mitsumoto H, Munsat TL, eds. Amyotrophic Lateral Sclerosis: A Guide for Patients and Families, 2nd ed. New York: Demos; 2001:113-132.
120. Krivickas LS. Exercise in neuromuscular disease. J Clin Neuromusc Dis. 2003;5:29-39.
121. Kurtzke JF, Beebe GW. Epidemiology of amyotrophic lateral sclerosis: 1. A case-control comparison based on ALS deaths. Neurology. 1980;30:453-462.
122. Roelofs-Iverson RA, Mulder DW, Elveback LR, et al. ALS and heavy metals: a pilot case-control study. Neurology. 1984;34:393-395.
123. Granieri E, Carreras M, Tola R, et al. Motor neuron disease in the province of Ferrara, Italy, in 1964-1982. Neurology. 1988;38:1604-1608.
124. Armon C, Kurland LT, Daube JR, et al. Epidemiologic correlates of sporadic amyotrophic lateral sclerosis. Neurology. 1991;41:1077-1084.
125. Strickland D, Smith SA, Dolliff G, et al. Physical activity, trauma, and ALS: a case-control study. Acta Neurol Scand. 1996;94:45-50.
126. Longstreth WT, McGuire V, Koepsell TD, et al. Risk of amyotrophic lateral sclerosis and history of physical activity. Arch Neurol. 1998;55:201-206.
127. Scarmeas N, Shih T, Stern Y, et al. Premorbid weight, body mass, and varsity athletics in ALS. Neurology. 2002;59:773-775.
128. Kilmer DD. Response to resistive strengthening exercise training in humans with neuromuscular disease. Am J Phys Med Rehabil. 2002;81(suppl):S121- S126.
129. Olsen DB, Orngreen MC, Vissing J. Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy. Neurology. 2005;64:1064-1066.
130. Kilmer DD, McCrory MA, Wright NC, et al. The effect of a high resistance exercise program in slowly progressive neuromuscular disease. Arch Phys Med Rehabil. 1994;75:560-563.
131. Bohannon RW. Results of resistance exercise on a patient with amyotrophic lateral sclerosis: a case report. Phys Ther. 1983;63:965-968.
132. Drory VE, Goltsman E, Reznik G, et al. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2001;191:133-137.
133. Pinto AC, Alves M, Nogueira A, et al. Can amyotrophic lateral sclerosis patients with respiratory insufficiency exercise? J Neurol Sci. 1999;169:69-75.
134. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996;39:147-157.
135. Liebetanz D, Hagermann K, von Lewinski F, et al. Extensive exercise is not harmful in amyotrophic lateral sclerosis. Eur J Neurosci. 2004;20:3115-3120.
136. Newrick PG, Langton-Hewer R. Pain in motor neuron disease. J Neurol Neurosurg Psychiatry. 1985;48:838-840.
137. Kanaan N, Sawaya R. Nocturnal leg cramps. Clinically mysterious and painful-but manageable. Geriatrics. 2001;56:34, 39-42.
138. Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2004;1:CD004156.
139. Carter GT, Miller RG. Comprehensive management of amyotrophic lateral sclerosis. Phys Med Rehab Clin. 1998;9:271-284.
140. Norris FH, U KS, Sachais B, et al. Trial of baclofen in amyotrophic lateral sclerosis. Arch Neurol. 1979;36:715-716.
141. Marquardt G, Lorenz R. Intrathecal baclofen for intractable spasticity in amyotrophic lateral sclerosis. J Neurol. 1999;246:619-620.
142. Restivo DA, Lanza S, Marchese-Ragona R, et al. Improvement of masseter spasticity by botulinum toxin facilitates PEG placement in amyotrophic lateral sclerosis. Gastroenterology. 2002;123:1749-1750.
143. Winterholler MG, Heckmann JG, Hecht M, et al. Recurrent trismus and stridor in an ALS patient: successful treatment with botulinum toxin. Neurology. 2002;58:502-503.
144. Mezaki T, Kaji R, Kohara N, et al. Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection. Neurology. 1996;46:845-846.
145. Rabkin JG, Wagner GL, Del Bene M. Resilience and distress among amyotrophic lateral sclerosis patients and caregivers. Psychosom Med. 2000;62:271-279.
146. Bocker FM, Seibold I, Neundorfer B. Disability in everyday tasks and subjective status of patients with advanced amyotrophic lateral sclerosis. Fortschr Neurol Psychiatr. 1990;58:224-236.
147. Ganzini L, Johnston WS, McFarland BH, et al. Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide. N Engl J Med. 1998;339:967-973.
148. Moore MJ, Moore PB, Shaw PJ. Mood disturbances in motor neurone disease. J Neurol Sci. 1998;160(suppl 1):S53-S56.
149. Veldink JH, Wokke JHJ, van der Wal G, et al. Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in The Netherlands. N Engl J Med. 2002;346:1638-1644.
150. Minkoff K, Bergman E, Beck AT, et at. Hopelessness, depression, and attempted suicide. Am J Psychiatry. 1973;130:455-459.
151. Beck AT, Brown G, Berchick RJ, et al. Relationship between hopelessness and ultimate suicide: a replication with psychiatric outpatients. Am J Psychiatry. 1990;147:190-195.
152. Mueller PS, Plevak DJ, Rummans TA. Religious involvement, spirituality, and medicine: implications for clinical practice. Mayo Clin Proc. 2001;76:1225-1235.
153. King DE, Bushwick B. Beliefs and attitudes of hospital inpatients about faith healing and prayer. J Fam Pract. 1994;39:349-352.
154. Daaleman TP, Nease DE Jr. Patient attitudes regarding physician inquiry into spiritual and religious issues. J Fam Pract. 1994;39:564-568.
155. Ehman JW, Ott BB, Short TH, et al. Do patients want physicians to inquire about their spiritual or religious beliefs if they become gravely ill? Arch Intern Med. 1999;159:1803-1806.
156. Gundersen L. Faith and healing. Ann Intern Med. 2000;132:169-172.
157. Koenig HG. Religion, spirituality, and medicine: application to clinical practice. JAMA. 2000;284:1708.
158. Koenig HG, McCullough M, Larson D. Handbook of Religion and Health. New York: Oxford University Press; 2000.
159. Fitchett G, Peterman AH, Cella DF. Spiritual beliefs and quality of life in cancer and HIV patients. Presented at the Third World Congress on Psycho-Oncology, New York, NY, 1996.
160. Cited by Mytko JJ, Knight SJ. Body, mind and spirit: towards the integration of religiosity and spirituality in cancer quality of life research. Psychooncology. 1999;8:439-450.
161. Riley BB, Perna R, Tate DG, et al. Types of spiritual well-being among persons with chronic illness: their relation to various forms of quality of life. Arch Phys Med Rehabil. 1998;79:258-264.
162. Brady MJ, Peterman AH, Fitchett G, et al. A case for including spirituality in quality of life measurement in oncology. Psychooncology. 1999;8:417-428.
163. Cotton SP, Levine EG, Fitzpatrick CM, et al. Exploring the relationships among spiritual well-being, quality of life, and psychological adjustment in women with breast cancer. Psychooncology. 1999;8:429-438.
164. Walsh SM, Bremer BA, Felgoise SH, et al. Religiousness is related to quality of life in patients with ALS. Neurology. 2003;60:127-1529.
165. Bremer BA, Walsh SM, Simmons Z, et al. Factors supporting quality of life over time for individuals with amyotrophic lateral sclerosis: the role of positive self-perception and religiosity. Ann Behav Med. 2004;28:119-125.
166. Thorson JA, Powell FC. Meanings of death and intrinsic religiosity. J Clin Psychol. 1990;46:379-391.
167. Cartwright A. Is religion a help around the time of death? Public Health. 1991;105:79-87.
168. Alvarado KA, Templer DI, Bresler C, et al. The relationship of religious variables to death depression and death anxiety. J Clin Psychol. 1995;51:202-204.
169. Roberts JA, Brown D, Elkins T, et al. Factors influencing views of patients with gynecologic cancer about end-of-life decisions. Am J Obstet Gynecol. 1997;176:166-172.
170. Kaldjian LC, Jekel JF, Friedland G. End-of-life decisions in HIV-positive patients: the role of spiritual beliefs. AIDS. 1998;12:103-107.
171. Murphy PL, Albert SM, Weber CM, et al. Impact of spirituality and religiousness on outcomes in patients with ALS. Neurology. 2000;55:1581-1584.
172. Puchalski C, Romer AL. Taking a spiritual history allows clinicians to understand patients more fully. J Palliat Med. 2000;3:129-137.
173. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554.
174. Flaherty-Craig C, Simmons Z. Deficient social judgment in non-bulbar amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(suppl 2):52.
175. Flaherty-Craig CV, Simmons Z. Deficient social judgment in non-bulbar amyotrophic lateral sclerosis. Neurology. 2004;62(suppl 5): A323-A324.
176. Flaherty-Craig CV, Simmons Z. Deficient social judgment in amyotrophic lateral sclerosis. Neurology. 2005;64(suppl 1):A372.
177. Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59:1077-1079.
178. Lomen-Hoerth C, Murphy J, Langmore S, et al. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology. 2003;60:1094-1097.
179. Singer PA. Disease-specific advance directives. Lancet. 1994;344:594-596.
180. Singer PA, Thiel EC, Salit I, et al. The HIV-specific advance directive. J Gen Intern Med. 1997;12:729-735.
181. Berry SR, Singer PA. The cancer specific advance directive. Cancer. 1998;82:1570-1577.
182. Benditt JO, Smith TS, Tonelli MR. Empowering the individual with ALS at the end-of-life: disease-specific advance care planning. Muscle Nerve. 2001;24:1706-1709.
183. Maxfield CL, Pohf JM, Colling K. Advance directives: a guide for patient discussions. Nurse Practitioner. 2003;28:38-47.
184. Ganzini L, Johnston WS, Silveira MJ. The final month of life in patients with ALS. Neurology. 2002;59:428-431.
185. Silverstein MD, Stocking CB, Antel JP, et al. Amyotrophic lateral sclerosis and life-sustaining therapy: patients' desires for information, participation in decisions making, and life-sustaining therapy. Mayo Clin Proc. 1991;66:906-913.
186. Young JM, Marshall CL, Anderson EJ. Amyotrophic lateral sclerosis patients' perspectives on use of mechanical ventilation. Health Soc Work. 1994;19:253-260.
187. Traynor BJ, Alexander M, Corr B, et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry. 2003;74:1258-1261.
188. Wasner M, Klier H, Borasio GD. The use of alternative medicine by patients with amyotrophic lateral sclerosis. J Neurol Sci. 2001;191:151-154.
189. Jenkinson C, Fitzpatrick R, Swash M, et al. The ALS health profile study: quality of life of amyotrophic lateral sclerosis patients and carers in Europe. J Neurol. 2000;415:835-840.
190. Woolley J, Ringel S. Caregiver quality of life in ALS: Relationship between patient health status and caregiver health-related quality of life, role satisfaction, and workforce participation [Abstract]. In: Proceedings of the Eighth International Symposium on Amyotrophic Lateral Sclerosis and Motor Neuron Disease; Glasgow; November 1997:33.
191. Krivickas LS, Shockley L, Mitsumoto H. Home care of patients with amyotrophic lateral sclerosis (ALS). J Neurol Sci. 1997;152(suppl 1):S82-S89.
192. Mitsumoto H. Caregiver assessment: summary. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3(suppl 1):S31-S34.
193. Murphy-Reiley VB, Simmons Z, Walsh SM, et al. Factors that predict quality of life and psychological morbidity in caregivers of patients with amyotrophic lateral sclerosis: a pilot study. Neurology. 2001;56(suppl 3):A200-A201.
194. Soros G, Madrick J. The international crisis: an interview. New York Review of Books. 1999;46:36-37, 38, 40.
195. Carr D. A 'good death' for whom? Quality of spouse's death and psychological distress among older widowed persons. J Health Soc Behav. 2003;44:215-232.
196. Oliver D. Ethical issues in palliative care-an overview. Palliat Med. 1993;7(suppl 2):15-20.
197. Stille A. Address delivered to the Medical Classes of the University of Pennsylvania, April 10, 1884. Med News. 1884;44:433-438.